logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available [see all tables in this series...]

Part (iv) Demographics of all women entering treatment

CountryYearMean age% Age <25% Age 35+
Bulgaria200523.365.82.9
Czech Republic200522.968.45.1
Denmark200531.730.535.8
Germany200531.237.032.2
Ireland200528.039.813.0
Greece200527.846.515.3
Spain(1)200432.522.240.9
France200528.042.522.8
Italy(2)200531.030.734.8
Cyprus200523.959.73.6
Latvia(3)200522.378.911.6
Lithuania200529.832.422.8
Luxembourg200527.043.022.0
Hungary200528.228.043.0
Malta200522.373.54.4
Netherlands200532.429.339.6
Austria(4)200532.722.243.7
Poland(1)200434.039.643.7
Portugal(3)200531.024.731.8
Romania200536.136.053.0
Slovenia(1)200425.849.010.0
Slovakia200528.551.219.7
Finland200525.658.012.0
Sweden200533.129.342.7
United Kingdom(5)200529.833.025.9
Turkey200526.540.012.0

Notes:

 Data were not available for: Belgium, Estonia, Norway. 

 (1) Last data available refer to 2004. 

 (2) Until 2004, 'all clients' reported clients continuing in or entering treatment in reported year; 2005 data are conformant with the TDI protocol. 

 (3) Data by gender refer to first treatments. 

 (4) Data refer to clients in substitution treatment only; figures for opioids as main drug and injecting use are 100%. 

 (5) Data relate to the period from 1 April 2004 to 31 March 2005 for UK. 

 See also 'General notes for interpreting data' on the Explanatory notes and help page

Sources:

 2006 Reitox national reports - Standard Table 3 See [Table TDI-1 Part (0)] for details on sources. 

Page last updated: Monday, 12 November 2007